A 2′-methoxyethyl-modified phosphorothioate ASO (OGX-011) inhibiting the clusterin gene has been used in different kinds of tumors and is currently in phase I/II trial in combination with cisplatin and gemcitabine, and in phase III in combination with docetaxel for the treatment of advanced NSCLC [46,47]. Here, CLU is linked to non-small cell lung carcinoma.